Johnson & Johnson

Johnson & Johnson’s latest antitrust settlement, FDA approvals and MedTech push show how the company balances pricing, patent cliffs and growth prospects.

Johnson & Johnson’s latest 2026 report reveals early promise for pasritamig + docetaxel in advanced prostate cancer and launches new, infection‑reduced aspiration catheters, boosting both drug and device portfolios.

Johnson & Johnson faces a Bayer lawsuit over prostate‑cancer advertising, a Blackstone partnership for AML drug bleximenib, and new long‑term data on TREMFYA, shaping its litigation, partnership and clinical landscape.

Johnson & Johnson may sell its $20 billion-plus orthopedics unit to boost cash and focus on high‑growth areas. Find out how the deal could reshape device pricing, supply‑chain costs and patient outcomes.

Johnson & Johnson’s Q4 2025 earnings and Caplyta’s Phase 3 data hint at a potential boost to its pharmaceutical segment, with promising antidepressant results and a solid 18 % annual return.

Johnson & Johnson’s flat share performance, strong earnings outlook, and focus on market‑access, biosimilar pipeline and strategic M&A reveal how the company balances innovation with realistic growth.

Johnson & Johnson’s February 2026 analyst shift: a buy‑to‑hold downgrade amid cost pressures, yet steady core strength and new mobile breast‑surgery simulator launch drive growth.

Johnson & Johnson’s legal win on Auris Health and RYBREVANT’s promising trial data point to new growth and profit opportunities for the company.

Johnson & Johnson’s new U.S. pricing‑tariff agreement balances Medicaid rebates with tariff savings, protecting margins ahead of Remicade’s 2025 patent cliff and positioning the company for targeted biologics acquisitions.

Johnson & Johnson’s share price falls after a $1.5 billion talc verdict—what this means for investors, regulators, and patient safety.